Research Summary

Dr. Marinoff's research focuses on identifying biomarkers (measurable substances relevant to a disease) to improve the accuracy of prognoses and on enhancing precision medicine approaches to cancer treatment. She has a special interest in sarcomas (certain tumors that arise in bone or connective tissue). She collaborates with teams in both the lab and the clinic to bring new biomarkers, risk prediction tools and treatment strategies into clinical trials, working toward better outcomes and decreased treatment side effects for pediatric, adolescent and young adult patients with cancer.

Education

  • Dartmouth College, BA, 2012, Neuroscience
  • Harvard Medical School, MD, 2017, Medicine
  • Boston Children’s Hospital/Boston Medical Center, Residency, 2020, Pediatrics
  • University of California, San Francisco, Fellowship, 2023, Pediatric Hematology/Oncology
  • University of California, San Francisco, 2023, Advanced Training in Clinical Research Certificate

Honors & Awards

  • 2024-present
    K12 Scholar, Helen Diller Family Comprehensive Cancer Center
  • 2023- 2024
    Outsmarting Osteosarcoma Young Investigator Research Award, MIB Agents
  • 2023- 2024
    Campini Foundation Award
  • 2023- present
    FDA-AACR Oncology Educational Fellow
  • 2023- present
    Alex’s Lemonade Stand Foundation Center of Excellence Scholar
  • 2021-2023
    Chan Zuckerberg Biohub Physician-Scientist Fellow
  • 2021-2023
    NIH T32 scholar
  • 2015
    Alexandra J. Miliotis Fellowship award in Pediatric Oncology, Harvard Medical School
  • 2007
    Siemens Competition, first-place team prize winner

Selected Publications

  1. Young EP, Marinoff AE, Lopez-Fuentes E, Sweet-Cordero EA. Osteosarcoma through the Lens of Bone Development, Signaling, and Microenvironment. Cold Spring Harb Perspect Med. 2024 Apr 02.  View on PubMed
  2. Shumock SS, Temple WC, Marinoff A, Aaronson K, Southworth E, Xirenayi S, Lee AG, Leung SG, Sweet-Cordero EA, Hermiston M, Higham C, Stieglitz E. Pre-and post-HSCT use of TKI therapy for fusion-driven B-ALL: A case series of five pediatric, adolescent and young adult patients. Cancer Rep (Hoboken). 2023 12; 6(12):e1901.  View on PubMed
  3. Meyer LK, Huang I, Huang BJ, Chung JH, Pawar A, Hermiston ML, Loh ML, Ohgami RS, Ruiz-Cordero R, Bhargava P, Marinoff AE. Hemophagocytic lymphohistiocytosis and clonally related T-cell malignancies in a pediatric patient. Pediatr Blood Cancer. 2023 Dec; 70(12):e30677.  View on PubMed
  4. Marinoff AE, Aaronson K, Agrawal AK, Braun BS, Golden C, Huang BJ, Michlitsch J, Southworth E, Thrall A, Vo KT, Stieglitz E. Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies. Pediatr Blood Cancer. 2023 06; 70(6):e30335.  View on PubMed
  5. Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, Doan D, Corson L, Mauguen A, Pinto N, Maese L, Colace S, Macy ME, Kim A, Sabnis AJ, Applebaum MA, Laetsch TW, Glade-Bender J, Weiser DA, Anderson M, Crompton BD, Meyers P, Zehir A, MacConaill L, Lindeman N, Nowak JA, Ladanyi M, Church AJ, Cherniack AD, Shukla N, Janeway KA. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol. 2023 03; 7:e2200334.  View on PubMed
  6. Lu KL, Menke JR, Ng D, Ruiz-Cordero R, Marinoff A, Stieglitz E, Gollapudi S, Singh K, Ohgami RS, Vohra P. Cytomorphologic features of pediatric-type follicular lymphoma on fine needle aspiration biopsy: case series and a review of the literature. J Am Soc Cytopathol. 2022 Sep-Oct; 11(5):281-294.  View on PubMed
  7. Marinoff AE, Ma C, Guo D, Snuderl M, Wright KD, Manley PE, Al-Sayegh H, Sinai CE, Ullrich NJ, Marcus K, Haas-Kogan D, Goumnerova L, London WB, Kieran MW, Chi SN, Fangusaro J, Bandopadhayay P. Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. J Neurooncol. 2017 Oct; 135(1):201-211.  View on PubMed

Go to UCSF Profiles, powered by CTSI